ReviewAnnals of medicine and surgery (2012)2021
Central Retinal Vein Occlusion in patients with COVID-19 infection: A systematic review.
Review in Annals of medicine and surgery (2012), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Relationship Between COVID-19 and Retinal Artery Occlusions.Journal of ophthalmology · 2026Review
- Relationship Between COVID-19 and Retinal Vein Occlusions.Journal of ophthalmology · 2025Review
- Retinal and Corneal OCT Results of Patients Hospitalized and Treated in the Acute Phase of COVID-19.Journal of clinical medicine · 2024Article
- Accelerated progression of diabetic retinopathy following severe COVID-19 infection.American journal of ophthalmology case reports · 2023Article
- Purtscher-like retinopathy in patients with COVID-19.American journal of ophthalmology case reports · 2023Article
- Risk of retinal vein occlusion following COVID-19 vaccination: a self-controlled case series.Eye (London, England) · 2023Article
- Eye disease and international travel: a critical literature review and practical recommendations.Journal of travel medicine · 2023Review
- A Literature Review of Pathophysiology, Clinical Manifestations, Medications and Optimal Dosage, Outpatient, and Post-hospitalization Use of Anticoagulation in COVID-19 Patients.Anatolian journal of cardiology · 2023Review
- Article
- Retinal Vein Occlusion Amongst People Vaccinated by mRNA- and Viral Vector- COVID-19 Vaccines: A Systematic Review.Clinical ophthalmology (Auckland, N.Z.) · 2023Review
- Facial palsy as a manifestation of COVID-19: A systematic review of cases.Health science reports · 2022Article
- Consecutive central and branch retinal vein occlusions in the same eye of a young healthy COVID-19 patient: A unique case report.American journal of ophthalmology case reports · 2022Article
- COVID-19 associated vasculitis: A systematic review of case reports and case series.Annals of medicine and surgery (2012) · 2022Review
- Ocular and Systemic Complications of COVID-19: Impact on Patients and Healthcare.Clinical ophthalmology (Auckland, N.Z.) · 2022Review
- Effect of the Coronavirus Disease 2019 Pandemic on Central Retinal Vein Occlusion.Journal of current ophthalmologyArticle
- Does High Altitude Increase the Risk of Retinal Vein Occlusion due to Elevated Serum Homocysteine?Journal of current ophthalmologyArticle
- Bilateral Simultaneous Central Retinal Vein Occlusion Secondary to COVID-19: A Case Report.Case reports in ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review summarizes the evidence on patients diagnosed with central retinal vein occlusion (CRVO) secondary to COVID-19. We searched PubMed and Google Scholar from its inception till June 2021. From an initial 55 publications, 10 studies provided specific information on COVID-19 patients with CRVO. Studies described 10 patients, 60% were male and the mean age was 39.3 ± 11.6 years. Blurred vision (40%) and decreased vision (50%) were the most common presenting complain. Symptom onset ranged from 5 days to 6 weeks after initial complaint of fever. Laboratory results showed elevated inflammatory markers and D-dimers in 60% of patients included in our review. Common treatment options were intravitreal anti-VEGF injections, steroids, and anticoagulants. Traditional co-morbidities like diabetes mellites, hypertension, and morbid obesity (hyperlipidemia) were observed in only 3/10 patients. The prognosis was excellent as all patients saw improvement in their condition. Our findings highlight the importance of identifying CRVO as an important complication of COVID-19 infection. Thus, physicians should not overlook the likelihood of CRVO in patients with COVID-19 infection and offer prompt treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.